Biotech
New Drug Technologies and Their Histories
Publication: AAAS: Keyword search for query
Author: Not available in collected metadata
Source published: 17/11/2026, 02:35:36 UTC
Briefing created: 22/11/2026, 03:17:34 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 19:49:30 UTC.
Briefings
The article analyzes drug development timelines for four technologies: fragment-based drug discovery (FBDD), DNA-encoded libraries (DEL), aptamers, and PROTAC degraders. It notes FBDD had FDA approval in 1996, DEL had no approved drugs as of the paper's writing, aptamers had two approvals over thirty years, and PROTACs had one approval in 2026. The text emphasizes that success requires long-term investment and specialized expertise, often involving in-house efforts or licensing from smaller companies.
Key points
- Fragment-based drug discovery achieved FDA approval in 1996.
- DNA-encoded libraries (DEL) had no approved drugs as of the paper's writing.
Context
This analysis examines historical and current timelines for four drug discovery technologies: fragment-based drug discovery (FBDD), DNA-encoded libraries (DEL), aptamers, and PROTAC degraders. The findings highlight varying success rates and approval dates, with PROTACs showing recent approval in 2026.
Limitations
The paper's author could not find any drugs approved via DEL as of the writing date. Timeline data for aptamers is limited to two approvals over thirty years. The article does not provide specific company names, geographic locations, or causal claims about why certain technologies succeeded or failed.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 03:17:34 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeibpg6hjkbwmrgpdqjkxmofcnzrk6flwud4f2jjj7xi5g6tjkzzyie